Changes to interests of a significant shareholder

RNS Number : 2177E

Alliance Pharma PLC

04 May 2017

 

For immediate release

4 May 2017

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder.   In accordance with AIM rule 17, the following details are now notified:

(a)  Identity of the significant shareholder: Mr Nigel Wray

(b)  Date of disclosure: 3 May 2017

(c)   Date of relevant change: 3 May 2017

(d)  Price, amount and class: 8,093,312 ordinary shares of 1p each; price not disclosed

(e)  Nature of transaction: sale of shares

(f)   Nature and extent of significant shareholder's interest: direct and indirect interests

(g)  Resultant shareholding: 1.63% (direct) and 3.68% (indirect) = 5.31% total

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Jane Glover
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:			ALLIANCE PHARMA PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	Placing shares and exercise of broker's option
3. Full name of person(s) subject to the notification obligation:		NIGEL WRAY
4. Full name of shareholder(s)  (if different from 3.):		Jarvis Investment Management Nominees Limited UBS PRIVATE BANKING NOMINEES LTD ROY NOMINEES LIMITED
5. Date of the transaction and date on which the threshold is crossed or reached:		3 May 2017
6. Date on which issuer notified:		3 May 2017
7. Threshold(s) that is/are crossed or reached:		5%

 

8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary shares GB0031030819

33,185,905

33,185,905

7,708,005

7,708,005

17,384,588

1.63%

3.68%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date

Exercise/ Conversion period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

25,092,593

5.3%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees 7,551,269 held by UBS Private Banking Nominees Ltd 156,736- Jarvis Investment Management Nominees Limited The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited   - 17,384,588
Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A
13. Additional information:	Figures are based on a total number of voting rights of 472,795,052
14. Contact name:	Nigel Wray
15. Contact telephone number:	020 7647 7647

 

END

 

 

HOLUGUAPAUPMGPC